Arsenal Biosciences Stock

arsenalbio.comHealthcareFounded: 2019Funding to Date: $85MM

ArsenalBio is a biotechnology company looking to develop efficacious and safe cellular therapies for patients with chronic diseases and develops cellular drug discovery tools designed to provide medicines for cancer treatment. The company's tools operate in cell genome engineering and cell manufacturing platforms, enabling hospitals to create T-cell medicines for cancer treatment.

Register for Details

For more details on financing and valuation for Arsenal Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Arsenal Biosciences.

Register Today

Arsenal Biosciences investors also invested in these private companies

Team

Management Team

Tarjei Mikkelsen
Chief Technology Officer
Kenneth Drazan MD
Co-Founder, Director, Chief Executive Officer, President and Board Member
Jane Grogan
Chief Scientific Officer

Board Members

Sean Parker
Parker Institute for Cancer Immunotherapy
Alexander Marson Ph.D
Brook Byers Ph.D
Kleiner Perkins
Beth Seidenberg MD
Westlake Village BioPartners

Other companies like Arsenal Biosciences in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$317.32MM
Sector
 
 
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$334.19MM

News

As innovations in cell therapy continue to grow, San Francisco-based ArsenalBio this week announced it raised a whopping $220 million in Series B funding, one of the largest rounds this year for a cell therapy venture.
The story behind ArsenalBio begins with Sean Parker’s Institute for Cancer Immunotherapy. Founded in 2016, the Institute has been instrumental in providing a space for the top researchers into cancer across different fields to collaborate and communicate on the latest breakthroughs in setting…
ArsenalBio, a South San Francisco, Calif.-based programmable cell therapy company, raised $85m in Series A financing round